This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investors Twice Shy on Cell Therapeutics

Paclitaxel is a great cancer-fighting drug, but at the cost of significant side effects. Xyotax combines paclitaxel with a proprietary molecule that is supposed to maintain, possibly enhance, paclitaxel's efficacy while reducing toxic side effects and the time required to administer the drug.

Tracking Stellar 3

Cell Therapeutics is putting Xyotax through its paces in a series of phase III studies. The most advanced of these studies, dubbed Stellar 3, is enrolling newly diagnosed non-small cell lung cancer patients to determine whether the combination of Xyotax and the chemo drug carboplatin increases survival compared with paclitaxel and carboplatin.

Though the lung cancer patients enrolled in this study haven't previously received chemotherapy, their cancer was diagnosed late, and they are in relatively poor health. On a performance scale of 0-5, Stellar 3 patients are ranked a 2, which means they can walk and care for themselves most of the time, but are too sick to work at all. (A patient with a performance status of 0 is fully active, while a performance status 5 patient is deceased.)

Results from the Stellar 3 study are expected in early 2005. Normally that's far enough in the future for investors not to get fixated on the event. But in this case, the data were expected in the fourth quarter of this year. Cell Therapeutics pushed back the projected data release because patients in the study seemed to be living longer than expected.

While taking care not to draw specific conclusions, Cell Therapeutics executives have been dropping hints in public that this Stellar 3 timeline pushback, at the very least, suggests that Xyotax is working. And they've done nothing to suppress comparisons between the Stellar 3 study and the recently concluded (and successful) OSI Pharmaceuticals (OSIP) study for its lung cancer drug Tarceva . Results from the Tarceva study were also delayed, as it turns out, because it showed that Tarceva boosted survival. (OSI's stock price, naturally, soared on the news.)
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TELK $2.75 -8.33%
ONXX $0.00 0.00%
CTIC $0.50 0.00%
BMY $72.18 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs